GlassScriptPhysician profile
Stacey N Akers
NPI 1639204829
$3,716.12
in general payments reported to CMS, 2019-2025
33 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $57.08 · 2021: $14.92 · 2022: $419 · 2023: $868 · 2024: $826 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,834.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $711.54 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Eisai INC. | $604.65 | 2020-2025 | |
| Glaxosmithkline, LLC. | $427.31 | 2022-2025 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals LP | $373.72 | 2019-2025 | Lynparza |
| Abbvie INC. | $221.35 | 2022-2025 | Orilissa |
| Stryker Corporation | $149.99 | 2023 | 1688 |
| Genmab U.S., INC. | $132.88 | 2023-2025 | Tivdak |
| Novartis Pharmaceuticals Corporation | $125.04 | 2023-2025 | |
| Tesaro, INC. | $123.03 | 2019 | |
| Amgen INC. | $117.82 | 2019 | |
| Janssen Biotech, INC. | $114.12 | 2022-2025 | Rybrevant, Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $68.91 | 2022-2025 | Ninlaro, Fruzaqla |
| Exelixis INC. | $43.29 | 2023-2025 | Cabometyx |
| Avanos Medical | $41.33 | 2019 | |
| Incyte Corporation | $40.82 | 2024-2025 | Monjuvi, Pemazyre |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $39.14 | 2023 | |
| Geron Corporation | $36.90 | 2024-2025 | Rytelo |
| Pharmacyclics LLC, An Abbvie Company | $35.85 | 2022-2023 | Imbruvica |
| Ferring Pharmaceuticals INC. | $35.22 | 2025 | Adstiladrin |
| Genentech USA, INC. | $31.12 | 2023-2025 | Tecentriq, Phesgo, Itovebi |
| Karyopharm Therapeutics INC. | $30.33 | 2024 | Xpovio |
| Myriad Genetic Laboratories, INC. | $23.74 | 2023 | Mychoice Cdx |
| Astellas Pharma US INC | $20.54 | 2023 | Veozah |
| Genzyme Corporation | $20.51 | 2023 | |
| Jazz Pharmaceuticals INC. | $19.83 | 2024 | |
| Rigel Pharmaceuticals, INC. | $17.50 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Seagen INC. | $17.33 | 2023 | Adcetris |
| Accord Healthcare, INC. | $16.84 | 2025 | |
| Adc Therapeutics America, INC. | $16.62 | 2025 | |
| Alexion Pharmaceuticals, INC. | $16.60 | 2025 | Ultomiris |
| Pharmacosmos Therapeutics INC. | $14.65 | 2023 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $14.43 | 2023 | Libtayo |
| Pharmaessentia USA Corporation | $13.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Akers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.